Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Genprex Inc (GNPX)

Genprex Inc (GNPX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,638
  • Shares Outstanding, K 2,099
  • Annual Sales, $ 0 K
  • Annual Income, $ -30,860 K
  • 60-Month Beta -0.54
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.58
Trade GNPX with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 75.78%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -2.30
  • Number of Estimates 1
  • High Estimate -2.30
  • Low Estimate -2.30
  • Prior Year -6.00
  • Growth Rate Est. (year over year) +61.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.09 +5.26%
on 04/26/24
2.74 -19.71%
on 05/07/24
-0.01 (-0.45%)
since 04/24/24
3-Month
2.09 +5.26%
on 04/26/24
5.41 -59.33%
on 03/06/24
-2.16 (-49.54%)
since 02/23/24
52-Week
2.09 +5.26%
on 04/26/24
42.40 -94.81%
on 06/02/23
-29.00 (-92.95%)
since 05/24/23

Most Recent Stories

More News
Genprex (NASDAQ: GNPX) Announces Positive Preclinical Data Supporting NPRL2 Gene Therapy

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The company today announced that its research collaborators...

GNPX : 2.20 (-0.45%)
Genprex (NASDAQ: GNPX) Closes on $6.5M Registered Direct Offering

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has closed on its registered direct offering. The offering,...

GNPX : 2.20 (-0.45%)
Genprex (NASDAQ: GNPX) Announces $6.5M Registered Direct Offering

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. The company today announced its entry into definitive...

GNPX : 2.20 (-0.45%)
Genprex (NASDAQ: GNPX) Adds Korean Patent for Leading Drug Candidate to IP Portfolio

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has received a Notice of Patent Grant from the Korean...

GNPX : 2.20 (-0.45%)
Genprex (NASDAQ: GNPX) Preclinical Data to be Presented at AACR Annual Meeting

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will be presenting its research at next month’s 2024...

GNPX : 2.20 (-0.45%)
Genprex (NASDAQ: GNPX) Announces New Research Collaborations, Expansion of Nonclinical Programs

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is expanding its nonclinical programs into new indications....

GNPX : 2.20 (-0.45%)
Genprex (NASDAQ: GNPX) Announces Participation at BIO CEO & Investor Conference

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will be represented at the upcoming BIO CEO & Investor...

GNPX : 2.20 (-0.45%)
Genprex (NASDAQ: GNPX) Phase 2a Expansion of Acclaim-1 Clinical Study Enrolls, Doses First Patient

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has enrolled and dosed the first patient in the phase...

GNPX : 2.20 (-0.45%)
Genprex (NASDAQ: GNPX) Granted Orphan Drug Designation in Small Cell Lung Cancer

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes, was granted orphan drug designation (“ODD”)...

GNPX : 2.20 (-0.45%)
Genprex (NASDAQ: GNPX) to Present at BIO-Europe 2023

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that Catherine Vaczy, its EVP, general...

GNPX : 2.20 (-0.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Genprex Inc. operates as a biotechnology company. It discovers and develops immunogene therapies for cancer treatment as well as clinical research, gene therapies, consulting and other related medical services. The company's initial product candidate is Oncoprex(TM) immunogene therapy which treats non-small...

See More

Key Turning Points

3rd Resistance Point 2.44
2nd Resistance Point 2.39
1st Resistance Point 2.29
Last Price 2.20
1st Support Level 2.15
2nd Support Level 2.10
3rd Support Level 2.01

See More

52-Week High 42.40
Fibonacci 61.8% 27.00
Fibonacci 50% 22.24
Fibonacci 38.2% 17.49
Last Price 2.20
52-Week Low 2.09

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar